ArticleMicrobial cell factories2025
Protease production by Serratia liquefaciens NRC1 using fish gut waste as a sustainable approach to antimicrobial peptide generation and combating Candida auris acquired resistance.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antimicrobial Peptides as Eco-Innovative Therapeutics to Overcome Antifungal Pressure-Induced Resistance in Candida Infections.Current microbiology · 2026Review
- Beyond intrinsic resistance: novel insights into the emergence and management of resistance acquired in Candida auris upon antifungal exposure.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global rise of antimicrobial resistance has accelerated the search for sustainable and eco-friendly therapeutic alternatives. This study evaluates fish gut waste (FGW) as a low-cost, renewable substrate for producing antifungal peptides through the proteolytic activity of Serratia liquefaciens NRC1.
resultOptimization of protease production using statistical designs resulted in a fourfold increase in enzyme yield. The protease demonstrated stability at neutral pH and moderate temperatures (40-50 °C), and efficiently hydrolyzed complex proteins such as collagen and keratin. Peptides generated from FGW hydrolysis exhibited significant antifungal activity against Candida auris (C. auris), with a MIC₅₀ of 5.1 ± 0.08 mg/ml. Unlike fluconazole, repeated peptide exposure did not induce resistance, nor did it alter the expression levels of key resistance genes (CDR1, ERG11), as confirmed by qRT-PCR. Peptide profiling using MALDI-TOF/MS, coupled with in silico analysis via AMPfun, identified multiple candidates with predicted antifungal properties.
conclusionThis research highlights the potential of fish gut waste-derived peptides as a sustainable and effective antifungal strategy against C. auris, offering an alternative to conventional antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.